Adaptive Biotechnologies Corporation ADPT

Annual Quarterly

FY2025 · ended Dec 31, 2025 · Revenue $276.98M, +54.8% YoY · Filed Feb 26, 2026

Adaptive Biotechnologies Corporation (ADPT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $277.0 million and a net loss of $59.5 million. Free cash flow was -$48.9 million. As of Sep 30, 2026 it held $400.2 million in cash and investments and $73.6 million in total debt.

Revenue (TTM)
$298.01M
+17.9% vs year-ago TTM
Net income (TTM)
$-70.52M
+11.4% vs year-ago TTM
Operating cash flow (TTM)
$-4.28M
+92.9% vs year-ago TTM
Free cash flow (TTM)
$-8.82M
+86.0% vs year-ago TTM
EPS (TTM)
$-0.45
+15.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
153.98M
+3.6% vs prior year
Net cash
$326.59M
as of Sep 30, 2026
Operating margin
-16.2%
FY 2026

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
ADPT (Nasdaq)
Fiscal year ends
December 31
Incorporated in
WA
Headquarters
Seattle, WA
SEC filer status
Large accelerated filer
SEC CIK
1478320
Former names
Adaptive TCR Corp (until Jun 2, 2011)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
$277.0M
$179.0M
$170.3M
$185.3M
$154.3M
Operating income
-$57.1M
-$162.5M
-$227.0M
-$200.2M
-$209.0M
Net income
-$59.5M
-$159.5M
-$225.2M
-$200.2M
-$207.3M
Diluted EPS
-$0.39
-$1.08
-$1.56
-$1.40
—
Operating cash flow
-$46.0M
-$95.2M
-$156.3M
-$183.9M
-$192.7M
Free cash flow
-$48.9M
-$98.9M
-$167.0M
-$200.3M
-$254.5M
Total assets
$512.7M
$539.4M
$661.1M
$856.6M
$923.3M
Total liabilities
$287.7M
$336.9M
$352.9M
$392.5M
$319.2M
Stockholders' equity
$218.8M
$202.7M
$308.4M
$464.2M
$604.0M
Cash and investments
$240.2M
$256.0M
$346.4M
$498.2M
$570.2M
Total debt
$210.4M
$222.7M
$229.4M
$108.0M
$111.7M

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Nov 4, 2026 Sep 30, 2026
8-K Current report
Results of operations
 Nov 4, 2026 Nov 4, 2026
10-Q Quarterly report Aug 4, 2026 Jun 30, 2026
8-K Current report
Results of operations, Officer or director change
 Jul 29, 2026 Jul 24, 2026
8-K Current report
Material agreement, Agreement ended, New debt, Unregistered share sale, Other events
 Jun 22, 2026 Jun 15, 2026
8-K Current report
Other events
 Jun 15, 2026 Jun 15, 2026

All 832 Adaptive Biotechnologies Corporation SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.